Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) disclosed on Wednesday the receipt of the tentative approval from the US Food and Drug Administration for the generic version of Prolensa (bromfenac ophthalmic solution) 0.07% for treating ocular pain in patients.
In conjunction with the US FDA's tentative approval,the company has settled litigation with Bausch & Lomb Inc for Prolensa (bromfenac ophthalmic solution) 0.07%.
According to the company, Prolensa (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
For the last 12 months, the branded market sales of Prolensa Ophthalmic Solution 0.07% were approximately USD113m, concluded the company.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets